126 related articles for article (PubMed ID: 33589791)
1. Rates of genetic testing in patients prescribed drugs with pharmacogenomic information in FDA-approved labeling.
Young J; Bhattacharya K; Ramachandran S; Lee A; Bentley JP
Pharmacogenomics J; 2021 Jun; 21(3):318-325. PubMed ID: 33589791
[TBL] [Abstract][Full Text] [Related]
2. Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.
Vivot A; Boutron I; Ravaud P; Porcher R
Genet Med; 2015 Sep; 17(9):733-8. PubMed ID: 25521333
[TBL] [Abstract][Full Text] [Related]
3. Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine.
Mehta D; Uber R; Ingle T; Li C; Liu Z; Thakkar S; Ning B; Wu L; Yang J; Harris S; Zhou G; Xu J; Tong W; Lesko L; Fang H
Drug Discov Today; 2020 May; 25(5):813-820. PubMed ID: 32032705
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients.
Green DJ; Mummaneni P; Kim IW; Oh JM; Pacanowski M; Burckart GJ
Clin Pharmacol Ther; 2016 Jun; 99(6):622-32. PubMed ID: 26693845
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view.
Varnai R; Szabo I; Tarlos G; Szentpeteri LJ; Sik A; Balogh S; Sipeky C
Pharmacogenomics J; 2020 Jun; 20(3):380-387. PubMed ID: 31787752
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
[TBL] [Abstract][Full Text] [Related]
7. Clinical evidence supporting pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels.
Wang B; Canestaro WJ; Choudhry NK
JAMA Intern Med; 2014 Dec; 174(12):1938-44. PubMed ID: 25317785
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomic biomarker information in FDA-approved paediatric drug labels.
Kim T; Han N; Sohn M; Oh JM; Lee EK; Ji E; Kim IW
Basic Clin Pharmacol Toxicol; 2015 May; 116(5):438-44. PubMed ID: 25348905
[TBL] [Abstract][Full Text] [Related]
9. Characterizing Pharmacogenomic-Guided Medication Use With a Clinical Data Repository.
Mathias PC; Hendrix N; Wang WJ; Keyloun K; Khelifi M; Tarczy-Hornoch P; Devine B
Clin Pharmacol Ther; 2017 Aug; 102(2):340-348. PubMed ID: 28073152
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
Verbelen M; Weale ME; Lewis CM
Pharmacogenomics J; 2017 Oct; 17(5):395-402. PubMed ID: 28607506
[TBL] [Abstract][Full Text] [Related]
11. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling.
Schuck RN; Grillo JA
AAPS J; 2016 May; 18(3):573-7. PubMed ID: 26912182
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomic information in the Warning section of drug labels: A comparison between labels in the United States and those in five other countries/regions.
Imatoh T; Sai K; Saito Y
J Clin Pharm Ther; 2018 Aug; 43(4):493-499. PubMed ID: 29682780
[TBL] [Abstract][Full Text] [Related]
14. Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.
Reis-Pardal J; Rodrigues A; Rodrigues E; Fernandez-Llimos F
Pharmacogenomics J; 2017 Dec; 17(6):488-493. PubMed ID: 27241061
[TBL] [Abstract][Full Text] [Related]
15. Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression.
Rothschild AJ; Parikh SV; Hain D; Law R; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Shelton RC; Macaluso M; Brown K; Lewis D; Gutin A; Jablonski MR; Greden JF
Psychiatry Res; 2021 Feb; 296():113649. PubMed ID: 33360967
[TBL] [Abstract][Full Text] [Related]
16. Patients dispensed medications with actionable pharmacogenomic biomarkers: rates and characteristics.
Liu D; Olson KL; Manzi SF; Mandl KD
Genet Med; 2021 Apr; 23(4):782-786. PubMed ID: 33420348
[TBL] [Abstract][Full Text] [Related]
17. Economic Outcomes Following Combinatorial Pharmacogenomic Testing for Elderly Psychiatric Patients.
Jablonski MR; Lorenz R; Li J; Dechairo BM
J Geriatr Psychiatry Neurol; 2020 Nov; 33(6):324-332. PubMed ID: 31842673
[TBL] [Abstract][Full Text] [Related]
18. Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available.
Samwald M; Xu H; Blagec K; Empey PE; Malone DC; Ahmed SM; Ryan P; Hofer S; Boyce RD
PLoS One; 2016; 11(10):e0164972. PubMed ID: 27764192
[TBL] [Abstract][Full Text] [Related]
19. Few Disparities in Baseline Laboratory Testing After the Diuretic or Digoxin Initiation by Medicare Fee-For-Service Beneficiaries.
Maciejewski ML; Mi X; Curtis LH; Ng J; Haffer SC; Hammill BG
Circ Cardiovasc Qual Outcomes; 2016 Nov; 9(6):714-722. PubMed ID: 27756796
[TBL] [Abstract][Full Text] [Related]
20. Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals.
Downing NS; Shah ND; Neiman JH; Aminawung JA; Krumholz HM; Ross JS
Trials; 2016 Apr; 17():199. PubMed ID: 27079511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
